Tirzepatide
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Eli Lilly · Phase 1/2 · Active, not recruiting · Enrollment 190
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Part 1: ARO-INHBE | n/r | n/r | n/r | n/r | n/r |
| Part 1: Placebo | n/r | n/r | n/r | n/r | n/r |
| Part 2: ARO-INHBE + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| Part 2: Placebo + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| Part 3: ARO-INHBE | n/r | n/r | n/r | n/r | n/r |
| Part 3: Placebo | n/r | n/r | n/r | n/r | n/r |
| Part 3: ARO-INHBE + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| Part 3: Placebo + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.